***NEWS***Citizen Petition asks FDA to approve Cassava Alzheimer's med simufilam***
- A Citizen Petition is asking the FDA to approve Cassava Sciences' (SAVA +0.9%) Alzheimer's drug simufilam as well as immediately begin phase 4 trials.
- The petition, submitted by Andrej Tokmakov, included results of a 12-month interim analysis of an open-label analysis of the candidate.
- The petition argues that "no medication has shown this degree and duration of cognitive and behavioral improvement."
- Cassava has come under criticism due to allegations over the way it conducted prior simufilam clinical trials.
- Earlier this month, Cassava said it was beginning a phase 3 trial of simufilam.
Market Data 
Markets 
AI
